Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Return on Sales: 2018-2025

Historic Return on Sales for UroGen Pharma (URGN) over the last 6 years, with Sep 2025 value amounting to -1.71%.

  • UroGen Pharma's Return on Sales fell 41.00% to -1.71% in Q3 2025 from the same period last year, while for Sep 2025 it was -1.71%, marking a year-over-year decrease of 41.00%. This contributed to the annual value of -1.40% for FY2024, which is 17.00% down from last year.
  • As of Q3 2025, UroGen Pharma's Return on Sales stood at -1.71%, which was down 3.74% from -1.64% recorded in Q2 2025.
  • UroGen Pharma's 5-year Return on Sales high stood at -1.24% for Q4 2023, and its period low was -6.50% during Q1 2021.
  • For the 3-year period, UroGen Pharma's Return on Sales averaged around -1.44%, with its median value being -1.40% (2024).
  • Per our database at Business Quant, UroGen Pharma's Return on Sales soared by 2,865bps in 2021 and then tumbled by 41bps in 2025.
  • UroGen Pharma's Return on Sales (Quarterly) stood at -2.31% in 2021, then skyrocketed by 60bps to -1.71% in 2022, then spiked by 47bps to -1.24% in 2023, then decreased by 17bps to -1.40% in 2024, then crashed by 41bps to -1.71% in 2025.
  • Its last three reported values are -1.71% in Q3 2025, -1.64% for Q2 2025, and -1.51% during Q1 2025.